Aspect CureForge AI Competitors
Primary Input User‑provided clinical trial simulation JSON files (retrospective, blinded, prospective) Proprietary databases, literature, omics data, or wet‑lab experiments
Agent Architecture One simulation agent per simulation + general orchestrator + specialized meta‑agents Single‑model systems or multi‑agent for specific tasks (target ID, molecule design)
Agent Memory Persistent memory (JSON/SQLite) with context injected into each task cycle Stateless; no learning from prior cycles
Dynamic Agent Creation General agent autonomously generates synthetic simulations and spawns new agents with priority queue and resource‑aware scaling Fixed agent counts; no runtime expansion
Agent Retirement Automatically retires underperforming agents to free resources None
Cure Discovery Confidence scoring from aggregated reports, threshold‑based CURE_FINDING emission, LLM‑based scoring with RAG context Target identification or molecule design; no explicit "cure" declaration
Task Execution Optional handoff pipeline (verify → improve → research → hypothesize → innovate) with state passing Independent tasks without sequential reasoning
Meta‑Agents Literature synthesis and synthetic design agents for higher‑level reasoning None
External Data Sources ClinicalTrials.gov, PubMed, EU CTR, general web search (Tavily), plus plugin system Typically one or two sources
Cost Control LLM response caching, adaptive polling, circuit breakers, retries, cost‑aware scaling None reported
Scalability Unbounded, resource‑aware, Kubernetes‑ready Fixed capacity
Deployment Fully containerized (Docker, docker‑compose, Helm), Prometheus‑observable Proprietary cloud or on‑prem; no open observability stack
Target User Researchers with existing simulation datasets seeking autonomous cure analysis Pharma R&D teams conducting de novo drug discovery